Skip to main content
Home > Week in Review > Clinical Results

Chronological Index of : Clinical Results

 Current Issue
  • ADX71149: Phase IIa data

    Addex Therapeutics Ltd. (SIX:ADXN), Geneva, Switzerland Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Product: ADX71149, JNJ-40411813 Business: Neurology Molecular target: Metabotropic glutamate receptor subtype 2 (…

    Published on 2/10/2014
  • AR-13324: Phase I data

    Aerie Pharmaceuticals Inc. (NASDAQ:AERI), Bedminster, N.J. Product: AR-13324 Business: Ophthalmic Molecular target: Rho kinase; Norepinephrine transporter Description: Dual inhibitor of Rho kinase and the norepinephrine…

    Published on 2/10/2014
  • CRS-207: Updated Phase II data

    Aduro BioTech Inc., Berkeley, Calif. Product: CRS-207 Business: Cancer Molecular target: NA Description: Live attenuated strain of Listeria monocytogenes that expresses human mesothelin Indication: Treat pancreatic …

    Published on 2/10/2014
  • Decapeptyl triptorelin pamoate: Phase III data

    Debiopharm Group, Lausanne, Switzerland Ipsen Group (Euronext:IPN; Pink:IPSEY), Boulogne-Billancourt, France Actavis plc (NYSE:ACT), Dublin, Ireland Product: Decapeptyl triptorelin pamoate (Debio 8206 SC) Business: …

    Published on 2/10/2014
  • EB-1020 SR: Interim Phase IIa data

    Neurovance Inc., Cambridge, Mass. Product: EB-1020 SR Business: Neurology Molecular target: NA Description: Sustained-release formulation of a serotonin, norepinephrine and dopamine reuptake inhibitor that …

    Published on 2/10/2014
  • Eltoprazine: Updated Phase IIa data

    Amarantus Bioscience Holdings Inc. (OTCQB:AMBS), San Francisco, Calif. PsychoGenics Inc., Tarrytown, N.Y. ReqMed Co. Ltd., Tokyo, Japan Product: Eltoprazine Business: Neurology Molecular target: Serotonin (5-HT1A) …

    Published on 2/10/2014
  • Eluxadoline: Phase III data

    Furiex Pharmaceuticals Inc. (NASDAQ:FURX), Morrisville, N.C. Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Product: Eluxadoline (MuDelta) (JNJ-270189066) Business: Gastrointestinal Molecular target: Mu opioid …

    Published on 2/10/2014
  • Eluxadoline: Phase III data

    Furiex Pharmaceuticals Inc. (NASDAQ:FURX), Morrisville, N.C. Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Product: Eluxadoline (MuDelta) (JNJ-270189066) Business: Gastrointestinal Molecular target: Mu opioid …

    Published on 2/10/2014
  • Firdapse amifampridine: QT/QTc study data

    BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), Novato, Calif. Catalyst Pharmaceutical Partners Inc. (NASDAQ:CPRX), Coral Gables, Fla. Jazz Pharmaceuticals plc (NASDAQ:JAZZ), Dublin, Ireland Product: Firdapse amifampridine …

    Published on 2/10/2014
  • Flublok: Phase III data

    Protein Sciences Corp., Meriden, Conn. UMN Pharma Inc. (Tokyo:4585), Akita, Japan Astellas Pharma Inc. (Tokyo:4503), Tokyo, Japan Ildong Pharmaceutical Co. Ltd. (KSE:000230), Seoul, South Korea Product: Flublok (UMN-…

    Published on 2/10/2014
  • Flublok: Phase III data

    Protein Sciences Corp., Meriden, Conn. UMN Pharma Inc. (Tokyo:4585), Akita, Japan Astellas Pharma Inc. (Tokyo:4503), Tokyo, Japan Ildong Pharmaceutical Co. Ltd. (KSE:000230), Seoul, South Korea Product: Flublok (UMN-…

    Published on 2/10/2014
  • Imprime PGG: Additional Phase IIb data

    Biothera Inc., Eagan, Minn. Product: Imprime PGG Business: Cancer Molecular target: Complement receptor 3 (CR3) (CD11b) Description: Soluble beta glucan derived from the cell walls of Saccharomyces cerevisiae Indication…

    Published on 2/10/2014
  • Lenvatinib: Phase III data

    Eisai Co. Ltd. (Tokyo:4523), Tokyo, Japan SFJ Pharmaceuticals Inc., Pleasanton, Calif. Product: Lenvatinib (E7080) Business: Cancer Molecular target: Vascular endothelial growth factor (VEGF) receptor; Vascular …

    Published on 2/10/2014
  • Oral H1N1 influenza vaccine: Phase Ib data

    Vaxart Inc., San Francisco, Calif. Product: Oral H1N1 influenza vaccine (VXA-A1.1) Business: Infectious Molecular target: NA Description: Oral, monovalent vaccine against the H1N1 influenza virus Indication: Vaccinate …

    Published on 2/10/2014
  • Oxycodone DETERx: Phase II data

    Collegium Pharmaceutical Inc., Canton, Mass. Product: Oxycodone DETERx (COL-003) Business: Neurology Molecular target: Opioid receptor (OPR) Description: Extended-release oral oxycodone formulated with DETERx tamper …

    Published on 2/10/2014
  • Palbociclib: Final Phase II data

    Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif. Pfizer Inc. (NYSE:PFE), New York, N.Y. Product: Palbociclib (PD-0332991) Business: Cancer Molecular target: Cyclin dependent kinase 4 (CDK4); Cyclin dependent kinase 6 (…

    Published on 2/10/2014
  • PXVX0200: Interim Phase III data

    PaxVax Inc., Menlo Park, Calif. Product: PXVX0200 Business: Infectious Molecular target: NA Description: Live attenuated vaccine against Vibrio cholerae Indication: Prevent cholera infection Endpoint: Disease protection…

    Published on 2/10/2014
  • Renevia: Clinical trial data

    BioTime Inc. (NYSE-M:BTX), Alameda, Calif. Product: Renevia (formerly HyStem-Rx) Business: Transplant Molecular target: NA Description: Biocompatible, implantable hyaluronan and collagen-based hydrogel cell delivery …

    Published on 2/10/2014
  • RHB-104: Preliminary Phase I data

    RedHill Biopharma Ltd. (Tel Aviv:RDHL; NASDAQ:RDHL), Ramat-Gan, Israel Product: RHB-104 (formerly Myoconda) Business: Autoimmune Molecular target: NA Description: Capsule formulation of the generic antibiotics …

    Published on 2/10/2014
  • SDP051: Phase I data

    Adheron Therapeutics Inc., Berkeley, Calif. Product: SDP051 Business: Autoimmune Molecular target: Cadherin 11 (Cad-11) (CDH11) Description: Humanized mAb against cadherin 11 (Cad-11; CDH11) Indication: Treat rheumatoid…

    Published on 2/10/2014
  • Somatuline Depot: Additional Phase III data

    Ipsen Group (Euronext:IPN; Pink:IPSEY), Boulogne-Billancourt, France Teijin Pharma Ltd., Tokyo, Japan Product: Somatuline Depot (Somatuline Autogel - EU) lanreotide acetate (ITM-014) Business: Cancer Molecular target: …

    Published on 2/10/2014
  • Traumakine: Phase I/II data

    Faron Pharmaceuticals Ltd., Turku, Finland Product: Traumakine (FP-1201) Business: Pulmonary Molecular target: NA Description: Recombinant human interferon (IFN) beta-1a Indication: Treat acute respiratory distress …

    Published on 2/10/2014
  • Vyvanse lisdexamfetamine dimesylate: Development discontinued

    Shire plc (LSE:SHP; NASDAQ:SHPG), Dublin, Ireland Product: Vyvanse lisdexamfetamine dimesylate (S-877489) Business: Neurology Molecular target: Not available Description: Prodrug of amphetamine Indication: Adjunctive …

    Published on 2/10/2014
  • Andexanet alfa: Additional Phase II data

    Portola Pharmaceuticals Inc. (NASDAQ:PTLA), South San Francisco, Calif. Product: Andexanet alfa (PRT064445, PRT4445) Business: Hematology Molecular target: NA Description: Recombinant protein that reverses the …

    Published on 1/20/2014
  • APL-130277: Pilot trial data

    Cynapsus Therapeutics Inc. (TSX:CTH), Toronto, Ontario Product: APL-130277 Business: Neurology Molecular target: Dopamine receptor Description: Sublingual thin film strip formulation of apomorphine, a small molecule …

    Published on 1/20/2014

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993